GC304
Gene or cell therapy (subtype unspecified)
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05860569 NCT05860569 · Severe Hypertriglyceridemia Registry: NCT05860569 | 1 | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) (12 weeks); The incidence of dose limited tolerance (DLT) (12 weeks) 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Severe Hypertriglyceridemia: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| GC304: this drug | Stage not on record | Gene or cell therapy (subtype unspecified) | LPL (lipoprotein lipase) gene | not yet graded | No reviewed efficacy summary in this indication | |
| Icosapent Ethyl (Vascepa) | Approved | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3) | |
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Omega-3-Acid Ethyl Esters (Lovaza) | Approved | Small molecule | Triglyceride metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| DR10624 | Phase 3 | Protein / enzyme therapeutic | GLP-1R; GCGR; FGF21R | Partial signal | NCT06555640: Median triglyceride reduction: 74.5% (12.5 mg), 66.2% (25 mg), 68.9% (50 mg titration) vs 8.0% with placebo | |
| Pegozafermin | Phase 3 | Protein / enzyme therapeutic | FGFR1c/2c/3c–β-Klotho agonist | Partial signal | No reviewed efficacy summary in this indication | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Partial signal | NCT03011450: Percent Change in Fasting TG From Baseline to Week 12 (12 Weeks): K-877 -58.89% (IQR -71.69 to -38.42) vs Placebo -22.94% (IQR -43.98 to 9.67) NCT03001817: Percent Change of Fasting Triglyceride(TG) Levels From Baseline to Week 12 (12 Weeks): K-877 -56% (IQR -72.08 to -32.4) vs Placebo -7.97% (IQR -44.78 to 49.87) | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | No reviewed efficacy summary in this indication | |
| Volanesorsen (Waylivra) | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Partial signal | NCT02300233: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Volanesorsen Total -71.2% (95% CI -79.3 to -63.2) vs Placebo -0.9% (95% CI -13.9 to 12.2) | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SEFA-1024 | Phase 2(overall) | Small molecule | Hepatic triglyceride/VLDL synthesis pathway | Partial signal | No reviewed efficacy summary in this indication | |
| Solbinsiran | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| CTX310 | Phase 1 | Gene therapy / editing | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Extended-Release Niacin (Niaspan) | Discontinued | Small molecule | GPR109A (HCAR2) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow GC304 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.